PharmaShots | Incisive News in 3 Shots

Subscribe Now

GalXC RNAi candidate

Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

May 27, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us